Markets
Uber car
Getty Images

Uber slides after revenue miss, despite bookings guidance that is above Wall Street’s forecast

Uber’s stock had been on a tear, rising 42% in 2025, but this morning’s earnings revealed a Q1 miss on revenue.

Hyunsoo Rim
5/7/25 7:04AM

Uber dropped in premarket trading after the company’s Q1 results missed Wall Street estimates, weighed down by tepid ride-share growth. Revenue rose 14% to $11.5 billion, just shy of the $11.6 billion forecast, while operating income of $1.23 billion narrowly beat the $1.22 billion consensus, per FactSet.

Gross bookings — the total spent on rides, deliveries, and freight — climbed 18% to $42.8 billion but fell short of the $43.05 billion target. However, for Q2, Uber projects bookings of $45.75 billion to $47.25 billion, above the $45.8 billion analyst consensus compiled by FactSet.

UBER
Sherwood News

More than half (56%) of Uber’s revenue still comes from ride-sharing — a segment hit by rising insurance costs, weaker consumer spending, and looming competition from Tesla’s robotaxi push.

To counter these headwinds, Uber is ramping up its autonomous vehicle strategy, which CEO Dara Khosrowshahi called its “single greatest opportunity ahead.” In March, Uber began offering Waymo robotaxis in Austin, where they accounted for 20% of Uber rides that month, with Khosrowshahi also stating that the company has “quickly grown to an annual run-rate of 1.5 million Mobility and Delivery AV trips on Uber's network.”

This month, it announced deals with Chinese AV firms Momenta, WeRide, and Pony.ai to expand robotaxi services across Europe and the Middle East, adding to its 15-plus AV partnerships across ride-hail, delivery, and freight.

Uber is also doubling down on delivery, now 33% of revenue, with a $700 million acquisition of Turkish platform Trendyol Go, aiming to offset cooling North American demand.

Still, with Tesla’s robotaxi launch next month, a fresh FTC probe over subscription, and consumer confidence plunging, whether Uber’s pivot to AVs will pay off remains to be seen.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.